Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of Atenativ in congenital antithrombin deficiency during surgery or childbirth
MOH_2024-01-24_013046Phase 3Not yet recruiting
- Sponsor
- Octapharma
- Start
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of antithrombin III concentrate in congenital antithrombin deficiency (ATD) (3 arms), sponsored by Octapharma. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
antithrombin III concentrate
03
Conditions
congenital antithrombin deficiency (ATD)
Beyond the preview
Go deeper on MOH_2024-01-24_013046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-24_013046.